Background: Historically, hormone receptor-positive breast cancers showed better outcomes. We investigated the prognosis and clinical traits of single hormone receptor-positive tumors (ER+PR- or ER-PR+), comparing them with both double hormone-positive and hormone-negative breast cancers. Aims: Our study aims to assess the prognostic implications of breast cancers expressing a single hormone receptor, either estrogen receptor-positive (ER+PR-) or progesterone receptor-positive (ER-PR+), compared to those expressing both receptors or none. Material and Methods: We examined the clinical and biological features of 141 women with breast carcinoma. Patients were stratified as having double HR+, single HR+ (ER+PR- and ER-PR+), and double HR- tumors. Then correlations with clinicopathological character and survival were made. Results: 22 (15.6%) cases were single HR+ tumors, of which 19 (13.5%) were ER+PR- tumors and 3 (2.1%) were ER-PR+ tumors. In the HER2-group only 10.5% of the ER+PR+ group have a hazard of death, while the hazard of death was 60% and 11.1% in the single hormone receptor positive groups (ER+PR-/ER-PR+) and ER-PR-groups, respectively. Regarding HER2+ groups, it was observed that none of the ER+PR+ group have a hazard of death, while 33.3% and 40% of single hormone receptor positive groups (ER+PR-/ER-PR+) and ER-PR-groups respectively, have a death hazard. This was statistically significant (p = 0.017). Conclusion: Our study found that breast tumors expressing only one hormone receptor (ER-PR+ or ER+PR-) had distinct characteristics compared to tumors expressing both receptors or none. These single hormone receptor-positive tumors showed poorer 5-year survival rates, similar to tumors lacking both receptors.